Recurrent Gastric Cancer Clinical Trial
Official title:
A Phase II Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients
This is an open, non-randomized, multicenter Phase II study evaluating cisplatin plus TS-1
or oxaliplatin plus TS-1 as first-line therapy in predicted 'responder' to platinum and
fluoropyrimidine.
This study is planned in 3 centers in Singapore and Korea. A total of 30 subjects will be
enrolled into each treatment arms. Each centers will recruit 15-25 subjects predicted to be
'responder' to platinum and fluoropyrimidine. The study will consist of a prescreening
period, a screening period and a treatment period. A fresh tumour biopsy sample will be
obtained during the prescreening period for gene expression profiling.
As this is a genomics guided trial, obtaining tissue biopsies is vital to the conduct of the
trial.
Patients will have the primary in situ (requirement for entry into trial), endoscopic biopsy
performed prior to 1st cycle.
Gastric cancer is the world's second leading cause of cancer death. For patients with
unresectable disease or recurrent disease after surgery, the main therapeutic option is
chemotherapy. Chemotherapy can improve survival and quality of life in patients with
advanced disease when compared with best supportive care alone.
Despite a large number of randomized trials, there is no consensus as to the best agent or
regimen. In general, combination chemotherapy regimens provide higher response rates than do
single agent, however, this translates into only a modest improvement in outcome with a
trade off in increased treatment toxicities. The key challenge in managing patients with
advanced gastric cancer is to identify the appropriate drugs for patients who might benefit
for palliative chemotherapy.
Gastric cancer is a heterogeneous disease with differing chemosensitivities to anti-cancer
drugs. Current selection of standard therapy is often empirical. Gene expression profiling
has been shown to have the capability to dissect this heterogeneity allowing for
sub-classification and risk-stratification of cancers according to their biological features
and clinical outcome. Utilising gene expression data coupled with in-vitro, in-vivo or
clinical response data is a promising strategy that may enable clinicians to match the right
drug to the right patient.
The purpose of the study are:
1. Assess the feasibility of genomic-guided therapy
2. Evaluated treatment response of standard-of-care chemotherapy in an enriched patient
groups defined as 'responder' based on genomic-guided therapy
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01705340 -
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
Completed |
NCT00991952 -
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00982592 -
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
|
Phase 2 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT00098527 -
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
|
Phase 2 | |
Terminated |
NCT01249443 -
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
|
Phase 1 | |
Completed |
NCT01612546 -
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT00028535 -
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT01939275 -
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
|
N/A | |
Unknown status |
NCT01491217 -
A Study of Oraxol® in Gastric Cancer Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
Completed |
NCT00068380 -
A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
|
Phase 2 | |
Completed |
NCT00084617 -
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
|
Phase 2 | |
Terminated |
NCT00064259 -
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00089362 -
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
|
Phase 1 | |
Completed |
NCT03602079 -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
|
Phase 1/Phase 2 | |
Completed |
NCT00607594 -
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
|
Phase 2 |